CanSino (Convidecia) - versus control - for root pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

symptomatic Covid-19 0.43 [0.30, 0.60]< 10%1 study (1/-)100.0 %NAnot evaluable important-

safety endpoints 00

ischemic stroke 0.33 [0.01, 16.67]< 10%1 study (1/-)70.7 %NAnot evaluable non important-
Myocardial infarction 0.33 [0.01, 16.67]< 10%1 study (1/-)70.7 %NAnot evaluable non important-
pulmonary embolism 0.33 [0.01, 16.67]< 10%1 study (1/-)70.7 %NAnot evaluable non important-
serious adverse events (SAE), any 1.40 [0.62, 3.15]< 10%1 study (1/-)20.9 %NAnot evaluable non important-
severe adverse events 11.00 [1.42, 85.22]< 10%1 study (1/-)1.1 %NAnot evaluable non important-

reactogenicity (vaccines) endpoints 00

systemic adverse reaction, any, dose 1 20.24 [10.60, 38.63]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
systemic adverse reaction, any, dose 2 4.39 [2.05, 9.41]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.